Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the …
OA Cornely, A Alastruey-Izquierdo, D Arenz… - The Lancet infectious …, 2019 - thelancet.com
Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality.
Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and …
Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and …
Challenges in the diagnosis and treatment of mucormycosis
A Skiada, C Lass-Floerl, N Klimko, A Ibrahim… - Medical …, 2018 - academic.oup.com
The diagnosis and treatment of mucormycosis are challenging. The incidence of the disease
seems to be increasing. Hematological malignancies are the most common underlying …
seems to be increasing. Hematological malignancies are the most common underlying …
[HTML][HTML] A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India
Objectives To describe the epidemiology, management and outcome of individuals with
mucormycosis; and to evaluate the risk factors associated with mortality. Methods We …
mucormycosis; and to evaluate the risk factors associated with mortality. Methods We …
A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment
Mucormycosis due to Mucorales is reported at large numbers in uncontrolled diabetics
across India, but systematic multicenter epidemiological study has not been published yet …
across India, but systematic multicenter epidemiological study has not been published yet …
Mucormycosis
G Reid, JP Lynch III, MC Fishbein… - Seminars in respiratory …, 2020 - thieme-connect.com
Mucormycosis is an infection caused by a group of filamentous molds within the order
Mucorales. Infections may result from ingestion of contaminated food, inhalation of spores …
Mucorales. Infections may result from ingestion of contaminated food, inhalation of spores …
[HTML][HTML] Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
AJ Ullmann, JM Aguado, S Arikan-Akdagli… - Clinical Microbiology …, 2018 - Elsevier
Abstract The European Society for Clinical Microbiology and Infectious Diseases, the
European Confederation of Medical Mycology and the European Respiratory Society Joint …
European Confederation of Medical Mycology and the European Respiratory Society Joint …
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Background Mucormycosis is an uncommon invasive fungal disease with high mortality and
few treatment options. Isavuconazole is a triazole active in vitro and in animal models …
few treatment options. Isavuconazole is a triazole active in vitro and in animal models …
[HTML][HTML] Diagnosis of severe respiratory infections in immunocompromised patients
E Azoulay, L Russell, A Van de Louw, V Metaxa… - Intensive care …, 2020 - Springer
An increasing number of critically ill patients are immunocompromised. Acute hypoxemic
respiratory failure (ARF), chiefly due to pulmonary infection, is the leading reason for ICU …
respiratory failure (ARF), chiefly due to pulmonary infection, is the leading reason for ICU …
[HTML][HTML] Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
R Bellmann, P Smuszkiewicz - Infection, 2017 - Springer
Introduction Because of the high mortality of invasive fungal infections (IFIs), appropriate
exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials …
exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials …
[HTML][HTML] A new age in molecular diagnostics for invasive fungal disease: are we ready?
Invasive fungal diseases (IFDs) present an increasing global burden in
immunocompromised and other seriously-ill populations, including those caused by …
immunocompromised and other seriously-ill populations, including those caused by …